However, the use of an SHP2 inhibitor alone may be ineffective in most CRC cells, especially for cells with gain-of-function mutations of KRAS or BRAF (Chen et al., 2016; Mainardi et al., 2018). The gene discussed is KRAS; the disease is colorectal carcinoma.